Similar articles for PMID: 29496983

Year	Number of Results
2004	1
2011	1
2012	1
2013	1
2015	6
2016	17
2017	24
2018	20
2019	15
2020	22
2021	17
2022	9
2023	4
2024	0

1

Effects of Fasting on ¹⁸F-DCFPyL Uptake in Prostate Cancer Lesions and Tissues with Known High Physiologic Uptake.

Wondergem M, van der Zant FM, Vlottes PW, Knol RJJ. Wondergem M, et al. J Nucl Med. 2018 Jul;59(7):1081-1084. doi: 10.2967/jnumed.117.207316. Epub 2018 Mar 1. J Nucl Med. 2018. PMID: 29496983 Free article. Clinical Trial.

2

Intraindividual Comparison of ¹⁸F-PSMA-1007 and ¹⁸F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.

Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O, Reyneke F, Haberkon U, Kopka K, Sathekge M. Giesel FL, et al. J Nucl Med. 2018 Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21. J Nucl Med. 2018. PMID: 29269569 Free article. Clinical Trial.

3

Repeatability of Quantitative ¹⁸F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.

Jansen BHE, Cysouw MCF, Vis AN, van Moorselaar RJA, Voortman J, Bodar YJL, Schober PR, Hendrikse NH, Hoekstra OS, Boellaard R, Oprea-Lager DE. Jansen BHE, et al. J Nucl Med. 2020 Sep;61(9):1320-1325. doi: 10.2967/jnumed.119.236075. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924729 Free PMC article. Clinical Trial.

4

Simplified Methods for Quantification of ¹⁸F-DCFPyL Uptake in Patients with Prostate Cancer.

Jansen BHE, Yaqub M, Voortman J, Cysouw MCF, Windhorst AD, Schuit RC, Kramer GM, van den Eertwegh AJM, Schwarte LA, Hendrikse NH, Vis AN, van Moorselaar RJA, Hoekstra OS, Boellaard R, Oprea-Lager DE. Jansen BHE, et al. J Nucl Med. 2019 Dec;60(12):1730-1735. doi: 10.2967/jnumed.119.227520. Epub 2019 Apr 18. J Nucl Med. 2019. PMID: 31000583 Free article.

5

Prospective Evaluation of ¹⁸F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management.

Song H, Harrison C, Duan H, Guja K, Hatami N, Franc BL, Moradi F, Aparici CM, Davidzon GA, Iagaru A. Song H, et al. J Nucl Med. 2020 Apr;61(4):546-551. doi: 10.2967/jnumed.119.231654. Epub 2019 Oct 18. J Nucl Med. 2020. PMID: 31628216 Free article. Clinical Trial.

6

PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.

Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY. Rowe SP, et al. Mol Imaging Biol. 2016 Jun;18(3):411-9. doi: 10.1007/s11307-016-0957-6. Mol Imaging Biol. 2016. PMID: 27080322 Free PMC article. Clinical Trial.

7

The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study.

Harsini S, Saprunoff H, Alden T, Mohammadi B, Wilson D, Bénard F. Harsini S, et al. J Nucl Med. 2021 Jan;62(1):81-87. doi: 10.2967/jnumed.120.246983. Epub 2020 May 8. J Nucl Med. 2021. PMID: 32385167 Free article. Clinical Trial.

8

Effect of forced diuresis during 18F-DCFPyL PET/CT in patients with prostate cancer: activity in ureters, kidneys and bladder and occurrence of halo artefacts around kidneys and bladder.

Wondergem M, van der Zant FM, Rafimanesh-Sadr L, Knol RJJ. Wondergem M, et al. Nucl Med Commun. 2019 Jun;40(6):652-656. doi: 10.1097/MNM.0000000000001007. Nucl Med Commun. 2019. PMID: 30855543

9

Prospective Comparison of PET Imaging with PSMA-Targeted ¹⁸F-DCFPyL Versus Na¹⁸F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.

Rowe SP, Li X, Trock BJ, Werner RA, Frey S, DiGianvittorio M, Bleiler JK, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG. Rowe SP, et al. J Nucl Med. 2020 Feb;61(2):183-188. doi: 10.2967/jnumed.119.227793. Epub 2019 Aug 26. J Nucl Med. 2020. PMID: 31451492 Free PMC article. Clinical Trial.

10

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. Chen Y, et al. Clin Cancer Res. 2011 Dec 15;17(24):7645-53. doi: 10.1158/1078-0432.CCR-11-1357. Epub 2011 Oct 31. Clin Cancer Res. 2011. PMID: 22042970 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

113 results

Results by year